- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Silver plans are exchange winners
Sixty-two percent of enrollees choose Silver plans
Today, the Department of Health and Human Services (HHS) announced that 3.3 million people have completed exchange enrollment through January, however, officials cannot say how many of the new sign ups have gone on to pay their initial premiums to health insurers.
In fourth quarter earnings reports, several national plans estimated their exchange enrollments:
Humana 200,000
WellPoint 500,000 on and off the exchanges
Aetna 135,000
Cigna 200,000 applications, with 20,000 paid enrollments
“Fifty-three percent more Americans are signed up today than were signed up by the end of December,” Kathleen Sebelius, HHS secretary, said in a press call. “In human terms, this means 1.16 additional Americans will have quality, affordable health coverage that’s there when they need it.”
HHS was able to drill down for the first time and report the sign ups by age and gender. In the federally facilitated and state exchanges, 25% of enrollees are between the ages of 18 and 34, and overall, 55% are women.
Likewise, the new report reveals plan selection by metal level. Because financial assistance is offered for Silver plans, they are the most popular, gaining 62% of enrollment.
Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health.
Listen
Independent Assessment of Syfovre Needed, Argues JAMA Ophthalmologist Viewpoint
December 7th 2023A California retinal specialist argues in a JAMA Ophthalmology viewpoint article that an independent panel of retinal specialists and statisticians should assess the data from clinical trials of Syfovre (pegcetacoplan) because of the lack of a complete FDA scientific analysis of the drug and of peer-reviewed publication.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
